NEW YORK (GenomeWeb News) – Caliper Life Sciences and Monogram Biosciences are among the firms that are being removed from the Nasdaq Biotechnology Index as of the open of the market on May 18.

The Nasdaq Biotech Index performs a semi-annual re-ranking of biotech firms that it considers for either adding or dropping from the Index. In this most recent re-ranking, it added four drug firms and dropped 16 firms.

The other research products firm that was dropped from the Index was Harvard Bioscience.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.